Finerenone Dosing Based on eGFR and Serum Potassium
Initiate finerenone at 10 mg daily if eGFR is 25-59 mL/min/1.73 m² or 20 mg daily if eGFR is ≥60 mL/min/1.73 m², but only when serum potassium is ≤4.8 mmol/L. 1
Initial Dosing Algorithm
The 2024 KDIGO guidelines provide clear, eGFR-based starting doses 1:
- eGFR ≥60 mL/min/1.73 m²: Start 20 mg once daily
- eGFR 25-59 mL/min/1.73 m²: Start 10 mg once daily
- **eGFR <25 mL/min/1.73 m²**: Not recommended per guidelines (though emerging real-world data suggests potential use down to eGFR >20 mL/min) 2
Critical prerequisite: Serum potassium must be ≤4.8 mmol/L before initiating finerenone at any dose.
Potassium-Guided Dose Management
When K+ ≤4.8 mmol/L:
- Continue current finerenone dose (10 or 20 mg)
- Uptitrate from 10 mg to 20 mg daily if patient was started on lower dose due to reduced eGFR
- Monitor potassium at 1 month after initiation, then every 4 months 1
When K+ 4.9-5.5 mmol/L:
- Continue finerenone at current dose (10 or 20 mg)
- Monitor potassium every 4 months
- This represents a key difference from traditional steroidal MRAs—finerenone can be safely continued in this range 1
When K+ >5.5 mmol/L:
- Hold finerenone immediately
- Adjust diet to reduce potassium intake
- Review and modify concomitant medications that may contribute to hyperkalemia
- Recheck potassium levels
- Restart at 10 mg daily when potassium falls to ≤5.0 mmol/L 1
Important Clinical Nuances
Dose titration is protective, not harmful: The pharmacokinetic/pharmacodynamic analyses from FIDELIO-DKD and FIGARO-DKD demonstrate that the potassium-guided dose titration protocol is highly effective at managing hyperkalemia risk 3, 4. Paradoxically, observed potassium levels actually decreased with higher finerenone doses in clinical trials—this inverse relationship reflects successful dose management rather than a pharmacologic effect.
The eGFR threshold matters: Finerenone is indicated for patients with eGFR >25 mL/min/1.73 m² per KDIGO 2024 guidelines 1. Real-world evidence suggests efficacy and safety may extend to eGFR 20-25 mL/min/1.73 m², but this remains off-guideline 2.
Combination therapy considerations: Finerenone can and should be added to RAS inhibitors and SGLT2 inhibitors in patients with type 2 diabetes and CKD 1. The antiproteinuric and renoprotective effects are independent and additive 3. Neither SGLT2 inhibitor nor GLP-1 receptor agonist use modifies finerenone's efficacy.
Common Pitfalls to Avoid
Drug interactions with CYP3A4 modulators: Finerenone is a sensitive CYP3A4 substrate 5. Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) are contraindicated. With moderate CYP3A4 inhibitors (e.g., erythromycin, verapamil, diltiazem), reduce finerenone dose or increase monitoring frequency. Avoid strong or moderate CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine) as they reduce finerenone exposure.
Don't confuse with steroidal MRAs: Unlike spironolactone or eplerenone, finerenone has significantly lower hyperkalemia risk at therapeutic doses 6. The potassium threshold of 4.8 mmol/L for initiation is specific to finerenone and reflects its improved safety profile.
Monitor early eGFR changes appropriately: Real-world data shows an initial eGFR decline of approximately -1.08 mL/min/1.73 m² per month in the first months after initiation 7. This early decline should not prompt discontinuation—it represents hemodynamic adaptation similar to that seen with RAS inhibitors and SGLT2 inhibitors, not true kidney injury.
Baseline potassium predicts response: Patients with lower baseline potassium levels experience greater increases in serum potassium after finerenone initiation 8. This doesn't contraindicate use but warrants closer early monitoring in patients with baseline K+ <4.0 mmol/L.